DGX — Quest Diagnostics Incorporated

Quest Diagnostics Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenues: $3.04 billion, up 10.2% year-over-year.
• Organic Revenue Growth: 10%.
• Adjusted Diluted EPS: $3.12, a 19.1% increase from $2.62 in Q2 2025.
• Operating Income: Reported at $459 million (15.1% of revenues), adjusted operating income at $502 million (16.5% of revenues).
• Volume Growth: Total requisitions increased by 13.1%, with organic volume growth at 13%.
• Cash from Operations: $875 million year-to-date, compared to $858 million in the prior year.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong demand from physicians, hospitals, and consumers, particularly through collaborations with Corewell Health and Fresenius Medical Care.
• Innovations: Continued investment in automation and AI to enhance operational efficiency and customer engagement.
• Consumer Health Expansion: Increased revenue from questhealth.com and new wellness panels, including a thyroid test offering.
• Advanced Diagnostics: Double-digit revenue growth in key areas such as cardiometabolic, autoimmune, brain health, and oncology.
• New Partnerships: Successful Co-Lab agreements with hospitals, including a new partnership with a regional health system in California.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated to $11.95 billion - $12.05 billion for 2026, reflecting an 8.3% to 9.2% growth rate.
• EPS Guidance: Reported EPS expected between $9.97 and $10.17; adjusted EPS between $11.05 and $11.25.
• Operational Expectations: Anticipated cash from operations of approximately $1.8 billion and capital expenditures around $550 million.
• Margin Outlook: Operating margin expected to expand year-over-year despite increased expenses related to Project Nova and fuel costs.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressure: Total revenue per requisition declined by 2.8% due to the business mix from Corewell and Fresenius. However, adjusted revenue per requisition increased by 2.9%.
• ACA Impact: Anticipated 30 basis point headwind from the expiration of ACA subsidies, though not significantly affecting current performance.
• Bad Debt Concerns: While management reported no significant changes in bad debt, there are industry-wide concerns regarding hospital collections and bad debt trends.
• PAMA Reimbursement Risks: Uncertainty surrounding potential reimbursement outcomes from the PAMA data collection process and the need for the RESULTS Act to mitigate cuts.

5. Notable Q&A Insights

• Hospital Relationships: Strong growth in both reference and Co-Lab business segments, with no signs of slowdown in demand or bad debt exposure.
• Utilization Trends: Continued robust utilization driven by chronic conditions and consumer engagement in health management.
• Oncology Testing: New York State approval for the Haystack MRD test opens significant market opportunities, with ongoing efforts to drive reimbursement and adoption.
• Consumer Testing Growth: High double-digit growth in the Alzheimer’s testing segment, with new payer coverage expected to drive further adoption.
• Operational Challenges: Discussions on the impact of rising fuel costs and Nova expenses on margins, but overall confidence in maintaining margin expansion.

This summary encapsulates the key aspects of Quest Diagnostics' Q2 2026 earnings call, highlighting financial performance, strategic initiatives, guidance, and challenges faced by the company.